Brief: SK Biopharmaceuticals Q3 Operating Loss 9 Billion Won
10/11/2022 24:26
Nov 10 (Reuters) - SK Biopharmaceuticals Co Ltd
326030.KS :
* Q3 OPERATING LOSS 9 BILLION WON, UP 81% FROM YEAR EARLIER
Further company coverage: 326030.KS
(Reporting by Joyce Lee)
((JungYoon.Lee@thomsonreuters.com;))
Recent news on SK Biopharmaceuticals
See all newsBrief: Sk Biopharmaceuticals Co Signs Licensing-In Contract With 1St Biotherapeutics
US FDA pauses new enrollment in Biohaven's epilepsy drug trials (updated)
US FDA pauses new enrollment in Biohaven's epilepsy drug trials
Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
U.S. STOCKS ON THE MOVE-Meta, Kohl's, J.M. Smucker